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Abstract: Less-intense TSH suppression strategies can be used for differentiated thyroid cancer
(DTC) patients with a low recurrence risk, but their metabolic outcomes are not well known.
We aimed to evaluate changes in the serum cholesterol levels and the risk of hypercholesterolemia
according to postoperative TSH levels in 1092 female DTC patients receiving levothyroxine after total
thyroidectomy. The preoperative-to-follow-up change in total cholesterol (TC) levels in the TSH level
<0.03, 0.03–0.3, 0.3–2, and 2–5 mIU/L groups was −3.69 mg/dL (p = 0.006), +0.13 mg/dL (p = 0.926),
+12.46 mg/dL (p < 0.001), and +16.46 mg/dL (p < 0.001), respectively. When compared with TSH
levels of 0.03–0.3 mIU/L, those of 0.3–2 mIU/L were found to be associated with hypercholesterolemia
(adjusted odds ratio (AOR) = 1.86 and 5.08 for TC 200–240 and ≥240 vs. <200 mg/dL) and
hyper-low-density lipoprotein (LDL)-cholesterolemia (AOR = 2.76 for LDL-cholesterol ≥160 vs.
<130 mg/dL). Additionally, TSH levels of 2–5 mIU/dL were associated with hypercholesterolemia
(AOR = 2.85 and 6.95 for TC 200–240 and ≥240 vs. <200 mg/dL) and hyper-LDL-cholesterolemia
(AOR = 2.08 and 4.17 for LDL-cholesterol 130–159 and ≥160 mg/dL vs. <130 mg/dL). In patients with
normal TSH level maintenance following thyroidectomy, TC levels markedly increased, resulting in
an increased hypercholesterolemia prevalence. Metabolic derangement risk due to insufficient
levothyroxine replacement should be considered in the adoption of less-intense TSH suppression
strategies, postoperatively, in DTC patients.
Keywords: differentiated thyroid cancer; total thyroidectomy; thyroid stimulating hormone;
cholesterol; hypercholesterolemia
1. Introduction
The incidence of thyroid cancer has rapidly increased over the past few decades globally, and the
disease is now the most prevalent type of endocrine cancer [1,2]. Therapies aimed at thyroid-stimulating
hormone (TSH) suppression using exogenous levothyroxine are the mainstays in the postoperative
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treatment of the inhibition of residual tumor tissue growth in patients with differentiated thyroid
carcinoma (DTC) [2]. Recommendations for the ideal TSH suppression intensity have changed over
time, and current management guidelines suggest the maintenance of a low-normal TSH level range
rather than a suppressed TSH level in patients with a low recurrence risk, because intensive TSH
suppression had no established benefit in this patient group [3,4].
However, the metabolic outcomes of these less-intense TSH suppression strategies are not well
known. Notably, recent studies showed that patients with hypothyroidism had hypercholesterolemia
more frequently despite maintaining normal serum TSH levels with levothyroxine replacement
therapy, indicating that normal TSH levels did not ensure sufficient thyroid hormone replacement
in patients with hypothyroidism [5,6]. Moreover, some studies on DTC patients have suggested
that thyroidectomized DTC patients with mildly suppressed TSH levels were the closest to having
a physiologic euthyroid status, whereas those with normal TSH levels had a hypothyroid status due to
relative triiodothyronine (T3) deficiency driven by the levothyroxine replacement therapy administered
to athyreotic patients [7,8]. This evidence raises the concern that the maintenance of normal TSH
levels in thyroidectomized patients may increase the risk of hypercholesterolemia associated with
insufficient replacement of thyroid hormones. Therefore, we aimed to evaluate changes in the serum
cholesterol levels and risk of hypercholesterolemia according to postoperative TSH levels in DTC
patients receiving levothyroxine after total thyroidectomy.
2. Materials and Methods
2.1. Study Participants
We reviewed 1841 women with DTC, who underwent total thyroidectomy from November 2005
to December 2015 aged 19–79 years and were followed-up with lipoprotein profile tests at 1–4 years
after thyroidectomy. We excluded those with preoperative serum total cholesterol levels ≥240 mg/dL
or missing values, triglyceride levels ≥400 mg/dL at follow-up, TSH levels ≥5 mIU/L or missing values
at follow-up, history of high-dose glucocorticoid use within a year and the use of lipid-lowering agents,
i.e., statins, ezetimibe, fibric acid derivatives, and omega-3 fatty acids, and those who had undergone
radioactive iodine scanning within a year (Figure S1). A total of 1092 women were finally analyzed.
The study protocol was approved by the Institutional Review Board of Severance Hospital, Seoul,
Korea (IRB number 4-2019-0407; approved on 20 June 2019), and the requirement for informed consent
was waived.
2.2. Data and Measurements
We obtained the earliest available follow-up medical records, including data on TSH levels and
lipoprotein profile at least one year after total thyroidectomy. Data on demographics, medical and
social history, and anthropometric measurements were obtained from all participants at follow-up.
Serum TSH and free thyroxine levels were measured by chemiluminescent microparticle immunoassay
(Architect System, Abbott Ireland Diagnostic Division, Lisnamuck, Longford, Co. Longford, Ireland;
the manufacturer’s reference ranges are 0.35–4.94 mIU/L for TSH and 0.7–1.48 ng/dL for fT4) at baseline
and follow-up. Lipid profile tests, including those for total cholesterol, triglyceride, and high-density
lipoprotein (HDL)-cholesterol, were conducted at follow-up by a routine Hitachi 7600 autoanalyzer
(Hitachi Instruments Service, Tokyo, Japan; the reference ranges are 142–240 mg/dL for total cholesterol,
48–200 mg/dL for triglyceride, and 40–75 mg/dL for HDL-cholesterol). Low-density lipoprotein
(LDL)-cholesterol levels were calculated using the Friedewald formula [9]. The cutoffs for total
cholesterol (200–239 and ≥240 mg/dL) and LDL-cholesterol (130–159 and ≥160 mg/dL) followed the
National Cholesterol Education Program Adult Treatment Panel III (NCEP/ATP III) and the Korean
Guidelines for the Management of Dyslipidemia criteria [10,11].
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2.3. Statistical Analyses
Participants were categorized into four groups according to their serum TSH levels at follow-up
(<0.03, 0.03–0.3, 0.3–2, and 2–5 mIU/L). Continuous variables were reported as mean ± standard
deviation or median (interquartile range). Categorical variables were reported as frequencies and
percentages. Intergroup comparisons were performed by Student’s t test or analysis of variance
for continuous variables, and a chi-squared test for categorical variables. Comparison of the
preoperative and follow-up total cholesterol values was performed by a paired t test. Least-square
means of ∆ total cholesterol, adjusted for age at follow-up, duration of follow-up, and preoperative
cholesterol level, were calculated and compared across the TSH group by analysis of covariance.
The association between follow-up TSH level (continuous) and preoperative-to-follow-up changes (∆)
in the total cholesterol was tested by multivariable linear regression models adjusted for age, follow-up
duration, body mass index (BMI, kg/m2), systolic blood pressure (SBP, mmHg), fasting glucose
level (mg/dL), cigarette smoking status (ever vs. never), and preoperative total cholesterol level
(mg/dL). Associations of follow-up TSH levels with hypercholesterolemia (total cholesterol level of
200–239 and ≥240 mg/dL) and hyper-LDL-cholesterolemia (LDL-cholesterol level of 130–159 and
≥160 mg/dL) were assessed by multinomial multivariable logistic regression models adjusted for the
aforementioned variables. Logistic regressions were further stratified by subgroups of age (<50 or
≥50 years), BMI (<25 or ≥25 kg/m2), diabetes presence, and preoperative cholesterol level (<200 or
≥200 mg/dL). Subgroup analyses and tests for interactions were performed against ordinal TSH
levels. Finally, as a sensitivity analysis, we repeated our regressions with a conventional logistic
model for hypercholesterolemia as binary outcomes (total cholesterol level ≥200 and ≥240 mg/dL;
LDL-cholesterol level ≥130 and ≥160 mg/dL). All tests were two-sided, and p < 0.05 was considered
statistically significant. All analyses were performed using R version 3.4.4 (R Foundation for Statistical
Computing, Vienna, Austria).
3. Results
3.1. Demographics and Descriptive Statistics
The median age of the patients at surgery was 51 (43–58) years, and the median age at follow-up
was 53 (45–60) years. The median duration after surgery was 2 (1.4–3.1) years. All patients
received levothyroxine for the suppression of TSH levels and/or replacement of the thyroid hormone.
At follow-up, 473 (43.3%) patients had TSH levels <0.03; 394 (36.1%), 0.03–0.3; 164 (15%), 0.3–2;
and 61 (5.6%), 2–5 mIU/L. The descriptive statistics stratified by TSH group are summarized in Table 1.
The groups with low TSH levels below 0.3 mIU/L had a higher proportion of older participants,
who underwent earlier follow-up lipid profile tests, compared to the higher TSH level groups.
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Table 1. Descriptive statistics by TSH group.
Variables
TSH, mIU/L
p Value<0.03 0.03–0.3 0.3–2 2–5
(n = 473) (n = 394) (n = 164) (n = 61)
Age at surgery, years 50.6 ± 10 51.2 ± 11.2 47.6 ± 12 47.6 ± 12 0.001
Age at follow-up, years 52.7 ± 10.1 53.4 ± 11.2 50 ± 11.9 50.3 ± 11.8 0.002
Follow-up, years 2.2 ± 0.9 2.2 ± 0.9 2.3 ± 0.9 2.7 ± 1 <0.001
History of hypertension 145 (30.7%) 161 (40.9%) 48 (29.3%) 21 (34.4%) 0.007
History of diabetes 87 (18.4%) 79 (20.1%) 32 (19.5%) 10 (16.4%) 0.876
Ever smokers 26 (5.5%) 22 (5.6%) 11 (6.7%) 5 (8.2%) 0.805
Preoperative TSH * 1.89 ± 1.02 1.99 ± 1.01 1.9 ± 0.99 1.79 ± 1.08 0.385
Preoperative cholesterol 184.83 ± 28.49 184.34 ± 27.82 178.74 ± 27.6 177.23 ± 27.3 0.028
Body mass index, kg/m2 23.44 ± 3.07 23.98 ± 3.49 23.82 ± 3.67 24.03 ± 3.57 0.101
Systolic blood pressure, mmHg 124.73 ± 14.99 125.08 ± 15.46 123.66 ± 16.05 122.07 ± 13.3 0.438
Free T4, ng/dL † 1.55 ± 0.26 1.44 ± 0.32 1.31 ± 0.23 1.18 ± 0.23 <0.001
TSH, mIU/L 0.02 ± 0 0.09 ± 0.06 0.84 ± 0.45 3.16 ± 0.88 <0.001
Glucose, mg/dL 98.92 ± 19.58 101.29 ± 24.18 100.13 ± 20.71 94.7 ± 13.03 0.099
Total cholesterol, mg/dL 181.14 ± 30.79 184.47 ± 30.57 191.2 ± 32.44 193.69 ± 33.65 <0.001
Total cholesterol, mg/dL 0.001
<200 345 (72.9%) 269 (68.3%) 98 (59.8%) 33 (54.1%)
200–239 113 (23.9%) 113 (28.7%) 53 (32.3%) 23 (37.7%)
≥240 15 (3.2%) 12 (3.1%) 13 (7.9%) 5 (8.2%)
∆Total cholesterol, mg/dL −3.69 ± 28.85 0.13 ± 28.09 12.46 ± 29.84 16.46 ± 29.78 <0.001
Triglyceride, mg/dL 110.5 ± 56.54 114.8 ± 60.05 110.1 ± 61.73 132.18 ± 70.88 0.048
HDL-cholesterol, mg/dL 51.7 ± 11.72 51.2 ± 11.74 53.92 ± 11.24 51.49 ± 9.55 0.084
LDL-cholesterol, mg/dL 107.34 ± 28.4 110.32 ± 28.12 115.26 ± 29.44 115.76 ± 31.14 0.007
LDL-cholesterol, mg/dL 0.04
<130 376 (79.5%) 304 (77.2%) 126 (76.8%) 41 (67.2%)
130–159 81 (17.1%) 73 (18.5%) 24 (14.6%) 14 (23%)
≥160 16 (3.4%) 17 (4.3%) 14 (8.5%) 6 (9.8%)
Data are presented as mean ± standard deviation or frequency (%). * Preoperative TSH level data available in 929
patients. † Follow-up T4 level data available in 1009 patients. Abbreviations: HDL, high-density lipoprotein; LDL,
low-density lipoprotein; TSH, thyroid-stimulating hormone.
3.2. TSH and Total Cholesterol Level before and after Thyroidectomy
The preoperative TSH levels were comparable between the groups (Table 1). The lower
postoperative TSH level groups had higher preoperative cholesterol levels than the higher TSH
level groups. At postoperative follow-up, patients with higher TSH levels exhibited significantly
higher levels of total and LDL-cholesterol. Relative to the preoperative level, the total cholesterol levels
remained unchanged in patients with postoperative TSH levels of 0.03–0.3 mIU/L, but decreased in
those with TSH levels <0.03 mIU/L and markedly increased in those with TSH levels greater than
0.3 mIU/L after surgery (Figure 1A). The ∆ total cholesterol levels were −3.69 mg/dL (p = 0.006),
+0.13 mg/dL (p = 0.926), +12.46 mg/dL (p < 0.001), and +16.46 mg/dL (p < 0.001) in the TSH level
<0.03, 0.03–0.3, 0.3–2, and 2–5 mIU/L groups, respectively (p values calculated by a paired t test).
After adjusting for age at follow-up, follow-up duration, and preoperative total cholesterol levels,
the least-square means of ∆ total cholesterol were −3.00, +0.54, +10.62, and +13.44 mg/dL in the TSH
level <0.03, 0.03–0.3, 0.3–2.0, and 2–5 mIU/L groups, respectively (Figure 1B). In the multivariable
linear regression, ∆ total cholesterol was significantly associated with TSH levels at follow-up after
adjusting for age, follow-up duration, and preoperative total cholesterol level (Table 2). The association
remained significant after further adjusting for other possible confounders (Table 2).
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thyroid-stimulating hormone. 
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adjusted for age at follow-up, duration of follow-up, and preoperative cholesterol level. Model 3 was 
further adjusted for cigarette smoking status, BMI, SBP, and fasting glucose level. Abbreviations: 
BMI, body mass index; SBP, systolic blood pressure; SE, standard error; TSH, thyroid-stimulating 
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regression model was used for the sensitivity analysis, we observed associations between high TSH 
levels and hypercholesterolemia (total cholesterol level ≥200 and ≥240 mg/dL; LDL-cholesterol level 
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Figure 1. Preoperative-to-follow-up changes (∆) in total cholesterol level according to TSH
group. (A) Unadjusted means with intergroup comparisons by analysis of variance and Tukey’s
test. (B) Least-square means, adjusted for age, follow-up duration, and preoperative cholesterol
level, with intergroup comparisons by analysis of covariance and Tukey’s test. a p < 0.001 vs.
TSH < 0.03 mIU/L; b p < 0.001 vs. TSH 0.03–0.3 mIU/L; c p < 0.01 vs. TSH 0.03–0.3 mIU/L. LSM,
least-square mean; TSH, thyroid-stimulating hormone.
Table 2. Association between follow-up TSH level and ∆total cholesterol (mg/dL).
Model n β (SE) p Value
Model 1 1092 6.45 (1.11) <0.001
Model 2 1092 5.15 (1.03) <0.001
Model 3 1092 5.15 (1.03) <0.001
Coefficients are in mg/dL per 1 mIU/L increment in TSH level. Model 1 was unadjusted. Model 2 was adjusted
for age at follow-up, duration of follow-up, and preoperative cholesterol level. Model 3 was further adjusted
for cigarette smoking status, BMI, SBP, and fasting glucose level. Abbreviations: BMI, body mass index; SBP,
systolic blood pr ssure; SE, standard error; TSH, thyroid-stimulating hormone.
3.3. Association between TSH Level and Hypercholesterolemia after Thyroidectomy
At follow-up, the prevalence of hypercholesterolemia—defined by the levels of either total or
LDL-cholesterol—gradually increased in the higher TSH groups (Figure 2). In the multinomial
multivariable logistic regressio , we observed significantly higher odds for hypercholesterolemia
in association with higher TSH lev ls after adjusting for age, follow- p duration, preoperative
total cholesterol levels, and other variables (Table 3). Compared to TSH levels of 0.03–0.3 mIU/L,
those of 0.3–2 mIU/L were associated with 1.86 and 5.08 times higher od s for hyperchol sterolemi
(total cholesterol levels of 200–240 and ≥240 vs. <200 mg/dL) and 2.76 times the odds for
hyper-LDL-chol sterolemia (LDL-cholesterol ≥160 vs. <130 mg/dL), respectively. Similarly, TSH levels
of 2–5 mIU/dL were associated with 2.85- and 6.95-times higher odds for total cholesterol levels f
200–239 and ≥240 mg/dL, respectively; and 2.08 and 4.17 times hi her odds for LDL-cholesterol levels
of 130–159 and ≥160 mg/dL, respectively. There were significant linear trends f increasing odds
for hypercholesterolemia toward the higher TSH group. The associations and trends were similar,
with no significant heterogeneities, between the subgroups by age, BMI, diabetes, and preoperative
t tal cholester l level (Figure 3). Finally, when a binary logistic regression model was used for the
sensitivity analysis, we observed associations between high TSH levels and hypercholesterolemia
(total cholesterol level ≥200 and ≥240 mg/dL; LDL-cholesterol level ≥130 and ≥160 mg/dL) that were
similar t those identified in the multi omial analyses (Table S1).
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Figure 2. Prevalence of hypercholesterolemia at follow-up according to TSH group. (A) Prevalence
of hypercholesterolemia defined as total cholesterol level of 200–239 and ≥240 mg/dL. (B) Prevalence
of hypercholesterolemia defined as LDL-cholesterol level of 130–159 and ≥160 mg/dL. p for trend by
Mantel-Haenszel test. LDL, low-density lipoprotein; TSH, thyroid-stimulating hormone.
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Figure 3. Association between follow-up TSH group and hypercholesterolemia in subgroup
analysis. Multinomial multivariable logistic regressions were adjusted for age at follow-up,
follow-up period, cigarette smoking status, body mass index, systolic blood pressure, fasting glucose
level, and preoperative cholesterol level. CI, confidence interval; OR, odds ratio; LDL, low-density
lipoprotein; TSH, thyroid-stimulating hormone.
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Table 3. Association between follow-up TSH level and hypercholesterolemia.
Model
TSH,
mIU/L
n Total Cholesterol Level 200–239 mg/dL Total Cholesterol Level ≥240 mg/dL
Events OR (95% CI) p Value p forTrend Events OR (95% CI) p Value
p for
Trend
Model 1 <0.03 473 113 0.78 (0.57–1.06) 0.111 15 0.97 (0.45–2.12) 0.948
0.03–0.3 394 113 1 (reference) 12 1 (reference)
0.3–2 164 53 1.29 (0.86–1.92) 0.216 13 2.97 (1.31–6.74) 0.009
2–5 61 23 1.66 (0.93–2.95) 0.085 0.102 5 3.4 (1.13–10.25) 0.03 0.003
Model 2 <0.03 473 113 0.73 (0.52–1.02) 0.064 15 0.93 (0.42–2.07) 0.854
0.03–0.3 394 113 1 (reference) 12 1 (reference)
0.3–2 164 53 1.84 (1.18–2.87) 0.008 13 4.9 (2.05–11.72) <0.001
2–5 61 23 2.61 (1.37–4.98) 0.004 0.002 5 6.21 (1.89–20.34) 0.003 <0.001
Model 3 <0.03 473 113 0.74 (0.52–1.03) 0.078 15 1.04 (0.46–2.32) 0.930
0.03–0.3 394 113 1 (reference) 12 1 (reference)
0.3–2 164 53 1.86 (1.19–2.92) 0.007 13 5.08 (2.14–12.06) <0.001
2–5 61 23 2.85 (1.47–5.53) 0.002 0.001 5 6.95 (2.13–22.72) 0.001 <0.001
Model
TSH,
mIU/L
n LDL-Cholesterol Level 130–159 mg/dL LDL-Cholesterol Level ≥160 mg/dL
Events OR (95% CI) p Value p forTrend Events OR (95% CI) p Value
p for
Trend
Model 1 <0.03 473 81 0.9 (0.63–1.27) 0.544 16 0.76 (0.38–1.53) 0.444
0.03–0.3 394 73 1 (reference) 17 1 (reference)
0.3–2 164 24 0.79 (0.48–1.32) 0.369 14 1.99 (0.95–4.15) 0.068
2–5 61 14 1.42 (0.74–2.75) 0.295 0.953 6 2.62 (0.98–7.02) 0.056 0.02
Model 2 <0.03 473 81 0.84 (0.58–1.23) 0.377 16 0.73 (0.36–1.5) 0.396
0.03–0.3 394 73 1 (reference) 17 1 (reference)
0.3–2 164 24 0.99 (0.58–1.7) 0.972 14 2.66 (1.22–5.78) 0.014
2–5 61 14 2.04 (0.99–4.18) 0.053 0.306 6 3.9 (1.36–11.19) 0.012 0.003
Model 3 <0.03 473 81 0.84 (0.57–1.22) 0.357 16 0.85 (0.41–1.78) 0.668
0.03–0.3 394 73 1 (reference) 17 1 (reference)
0.3–2 164 24 1 (0.58–1.71) 0.991 14 2.76 (1.24–6.12) 0.012
2–5 61 14 2.08 (1.01–4.31) 0.048 0.298 6 4.17 (1.41–12.34) 0.01 0.002
Model 1 was unadjusted. Model 2 was adjusted for age at follow-up, duration of follow-up, and preoperative
cholesterol level. Model 3 was further adjusted for cigarette smoking status, body mass index, systolic blood
pressure, and fasting glucose level. Abbreviations: CI, confidence interval; OR, odds ratio; LDL, low-density
lipoprotein; TSH, thyroid-stimulating hormone.
4. Discussion
In this study, thyroidectomized DTC patients with mildly suppressed TSH levels (0.03–0.3 mIU/L)
at follow-up had total cholesterol levels that were comparable to those at the preoperative stage.
Patients with normal TSH levels at follow-up had total cholesterol levels that were significantly higher
than those at the preoperative stage. As a result, patients with normal TSH levels had a significantly
higher risk for hypercholesterolemia (both total cholesterol and LDL-cholesterol) than those with
mildly suppressed TSH levels.
TSH is the most sensitive marker for thyroid function evaluation, and thyroid function status is
generally assessed based on a reference TSH range defined in a healthy population with normal thyroid
function [12]. However, the concept that normal TSH levels is the therapeutic target for thyroid hormone
replacement is recently challenged. In a large population study by Peterson et al, levothyroxine-treated
participants with normal serum TSH levels were found to be taking statins more often than taking
euthyroid controls [5]. Similarly, meta-analysis by McAninch et al. showed that levothyroxine-treated
patients with normal serum TSH levels had higher serum total cholesterol and LDL-cholesterol levels
than did healthy controls [6]. This epidemiological evidence suggests that normal TSH levels do
not assure sufficient thyroid hormone replacement in patients with hypothyroidism and that serum
cholesterol levels may serve as an ancillary marker for adequacy of the replacement therapy [13].
Similarly, some evidence suggests that normal TSH levels in thyroidectomized patients may
correspond to insufficient replacement of thyroid hormone. In the previous studies, thyroidectomized
patients had lower TSH levels when their free T3 levels are similar to those at the preoperative stage
or those of controls with normal thyroid function [7,8,14,15]. More recently, Ito et al. compared the
preoperative and postoperative serum levels of the peripheral markers of thyroid function (lipoproteins,
sex hormone-binding globulin, and bone metabolic markers) in 133 patients with papillary thyroid
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carcinoma who underwent total thyroidectomy [7]. In that study, patients with mildly suppressed
TSH levels (0.03–0.3 mIU/L) showed no changes in the metabolic marker levels from the preoperative
levels, whereas patients with normal TSH levels (0.3–5 mIU/L) showed elevated LDL-cholesterol levels
and decreased bone turnover marker levels [7].
Thyroid hormones influence the function of various factors associated with cholesterol metabolism,
such as that of the LDL-cholesterol receptor, cholesterol ester transfer protein, hepatic lipase and
lipoprotein lipase, and the flow of bile acid in the liver [16,17]. Thus, insufficient replacement
of thyroid hormones in hypothyroidism may result in increased total and LDL-cholesterol levels,
which, in turn, may lead to atherosclerotic cardiovascular diseases [13]. We found that patients with
mildly suppressed TSH levels (0.03–0.3 mIU/L) had total cholesterol levels equivalent to those at the
preoperative stage, in line with the findings of Ito et al. [7], while patients with lower-normal TSH
levels (0.3–2 mIU/L) and upper-normal TSH levels (2–5 mIU/L) had progressively greater increases in
their total cholesterol levels after thyroidectomy. Furthermore, patients with lower-normal TSH and
upper-normal TSH levels had higher odds for hypercholesterolemia (adjusted odds ratios (AORs) for
total cholesterol levels ≥240 mg/dL: 5.08 and 6.95, respectively) and hyper-LDL-cholesterolemia (AORs
for LDL-cholesterol levels ≥160 mg/dL: 2.76 and 4.17, respectively) than those with mildly suppressed
TSH levels (0.03–0.3 mIU/L). These results suggest that patients with TSH level maintenance within
the normal range after total thyroidectomy may have a high risk of hypercholesterolemia induced by
the physiologically insufficient replacement of the thyroid hormone.
As, in addition to insufficient replacement, over-replacement of thyroid hormones may also
increase cardiovascular risk, it is important to balance the intensity of levothyroxine replacement
therapy [18]. Several reports have stated that subclinical hyperthyroidism increases the risk for heart
failure, atrial fibrillation, and cardiovascular disease-related and overall death [19]. However, unlike the
results in subclinical hyperthyroidism, the occurrence rate of adverse cardiovascular outcomes is
not known to increase when thyroidectomized patients or those receiving levothyroxine therapy
have mildly suppressed TSH levels [20,21]. Flynn et al. assessed patients receiving levothyroxine
replacement and reported that those with TSH levels < 0.04 mIU/L and TSH levels > 4 mIU/L had
increased risks for cardiovascular diseases and arrhythmias compared to patients with TSH levels
between 0.4 and 4 mIU/L [21]. However, the risk in patients with TSH levels between 0.04 and
0.4 mIU/L was not increased [21]. More recently, Hesselink et al. retrospectively assessed DTC patients
who underwent total thyroidectomy [20]. In that study, patients with TSH levels <0.02 mIU/L showed
higher cardiovascular mortality values than those with TSH levels >0.2 mIU/L, whereas patients with
TSH levels between 0.02 and 0.2 mIU/L did not [20]. Our results, along with those of previous studies,
suggest that a mildly suppressed TSH level (e.g., 0.03–0.3 mIU/L in our study) may be the metabolically
neutral TSH level that is associated with low cardiovascular risk in thyroidectomized DTC patients
receiving levothyroxine.
This study is unique and has strong clinical utility. To the best of our knowledge, this is the first
study to show that normal TSH levels are associated with increased hypercholesterolemia risk in DTC
patients receiving levothyroxine after total thyroidectomy. Although changes in the serum lipid levels
during thyroxine withdrawal after total thyroidectomy have been assessed in some studies, the risk
of hypercholesterolemia during levothyroxine therapy has not been [22–25]. Owing to the fact that
thyroid cancers are detected early these days, leading to a low risk, and that most DTC patients have
a favorable clinical course [26], the unsuppressed range of TSH may be applied to many such cases
according to current management guidelines [3,4]. Therefore, hypercholesterolemia associated with
insufficient replacement of the thyroid hormones may be a prevalent problem for many DTC patients
today, whereas the problem has rarely been addressed before as more intensive TSH suppression
therapy had been the common practice in the past.
Our study has some limitations that should be considered. First, normal aging may have
contributed to the incidence of postoperative hypercholesterolemia observed in our study. However,
based on our preoperative data, the slope of age-associated total cholesterol increment is estimated to
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be only 0.4 mg/dL per year of age. In the Korea National Health and Nutrition Examination Survey
2005, the slope of the age-cholesterol association in women was 1.2 mg/dL per year [27]. In this regard,
it is unlikely that the attained age at follow-up significantly contributed to hypercholesterolemia
incidence in our study. Second, our study was based on a single follow-up result after a relatively short
follow-up period. Furthermore, hard cardiovascular outcomes such as myocardial infarction, stroke,
and death were not assessed, although hypercholesterolemia is a major risk factor for cardiovascular
disease [28]. Third, our results may not be directly generalizable to male patients, because of the
potential interaction of sex with the relationship between thyroid function and lipid metabolism [23,29].
Fourth, as this was a single-center study mainly comprising middle-aged patients in Korea, the findings
should be interpreted with caution when applied to patients with different genetic, demographic,
or geographic backgrounds.
5. Conclusions
In conclusion, while the serum total cholesterol levels significantly increased when female DTC
patients maintained normal TSH levels with levothyroxine after total thyroidectomy, the total cholesterol
levels did not change in patients with mildly suppressed TSH levels. Accordingly, patients who
retained normal TSH levels after thyroidectomy had a higher risk of hypercholesterolemia and
hyper-LDL-cholesterolemia. Our study suggests that metabolic derangement risk owing to insufficient
levothyroxine replacement should be considered when less-intense TSH suppression is required in
postoperative DTC patients. Additionally, randomized control trials on the potential adverse outcomes
associated with thyroid dysfunction are needed to determine the optimal target range of postoperative
TSH in DTC patients after total thyroidectomy.
Supplementary Materials: The following are available online at http://www.mdpi.com/2077-0383/8/8/1106/s1,
Figure S1. Flowchart of the study population; Table S1. Association between follow-up TSH level and
hypercholesterolemia examined using conventional binary logistic regression.
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